SecBot SecBot

ERNA

Ernexa Therapeutics Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0000748592 Biotech & Drug Discovery
$1.94 −0.13 (−6.28%)
Oct 26 4:00 PM ET · prev $2.07
Market cap
$3.4M
Nano cap
Median target
$30.00
+1446% · range $30.00–30.00
Next earnings
Nov 5
in 9 days · EPS est. −$3.84
1 year
−93.5%
from $29.75 · Oct 27
30 days
−44.1%
from $3.47
52-week range
$1.94–47.00
at the low
Avg volume 20D
71.3K
Oct 7 spike 662.9K
Short interest
🔒 Subscribers only
Insider net
+$2.0M
1 buyer · 0 sellers · 12 mo
Filing reports
6
analyzed by SecBot
SecBot read BULLISH 6 reports · 90 days
Balance 0 bearish · 1 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 3/6 ·Next Earnings date, Nov 5, 2026
Strongest BULLISH Ernexa Therapeutics reported encouraging nonclinical safety results for its lead iPSC-derived cell therapy…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $2.0M. No open-market sales.

  • TrendDOWNTREND

    44% below its 50-day average. New closing low $1.94 on Oct 26.

Who's buying

13F
Top holderSharesValue
CITADEL ADVISORS LLC15,104$100.4K
VANGUARD FIDUCIARY TRUST CO8,336$55.4K
VANGUARD CAPITAL MANAGEMENT LLC5,684$37.8K
BlackRock, Inc.33$219.00
ASSETMARK, INC5$33.00
BNP PARIBAS FINANCIAL MARKETS1$7.00
Steward Partners Investment Advisory, LLC0$1.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action May 2026
12-month targets · 1 analysts

Price is below the lowest target. Median implies +1446%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
May 7, 2026Brookline Capital
INITIATE
INITIATEBuy
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 5, 2026
Earnings date
ERNA Q3 2026 Earnings Scheduled — 2026-11-05
Recent
Oct 22, 2026
FDA
Ernexa Therapeutics Highlights ERNA-101’s Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment
Leadership discusses recent FDA engagement, the technology underlying ERNA-101 and the development strategy supporting planned first-in-human…
Oct 6, 2026
Press release
Ernexa Therapeutics’ ERNA-101 Selected for Flash Talk Presentation at Nature Conferences’ Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center
Preclinical data highlighting ERNA-101’s potential to activate the ovarian cancer tumor microenvironment and enhance checkpoint blockade will be…
Oct 1, 2026
FDA
Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic
CEO Discusses How Addition of Accomplished Oncology Drug Developer Strengthens Ernexa Ahead of Clinical Development Following ERNA-101 Data…
Sep 30, 2026
FDA
Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND
Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no clinical pathology or…
Sep 29, 2026
Press release
Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy
Ernexa selected for the Emerging Track, recognizing the Company among emerging innovators in the cell and gene therapy sector

Insider ledger

Form 4
$2.0M
bought · 1 insider
$0
sold · 0 insiders
DateInsiderTypeValue
Aug 31, 2026
Luther Sanjeev
President and CEO
AWARD118,848 sh
Aug 31, 2026
Ratner Elena
Director
AWARD5,944 sh
Aug 31, 2026
Wexler William A.
Director
AWARD5,943 sh
Aug 31, 2026
Polinsky David
Director
AWARD5,083 sh
Aug 31, 2026
Cicala Peter
Director
AWARD5,943 sh
Aug 31, 2026
Cicala Peter
Director
AWARD5,083 sh
Aug 31, 2026
Bristol James Arthur
Director
AWARD8,320 sh
Aug 31, 2026
Bristol James Arthur
Director
AWARD5,083 sh

Earnings setup

Estimates
Nov 5
reports in 9 days
−$3.84
EPS estimate, this quarter
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$3.84-$3.84–-$3.84+0.0%$0.00
Next Q-$4.76-$4.76–-$4.76+0.0%$0.00
Current FY-$18.02-$18.02–-$18.02+0.0%$0.00
Next FY-$1.86-$1.86–-$1.86+0.0%$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Trading halts
Jul 15, 2026Volatility PauseResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 22, 2026 Press
Ernexa Therapeutics released a Virtual Investor segment discussing its pre-IND interaction with the FDA for lead…
Impact 3/10
Oct 22, 2026 FDA
Ernexa Therapeutics Highlights ERNA-101’s Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment
Leadership discusses recent FDA engagement, the technology underlying ERNA-101 and the development s
Oct 15, 2026 SEC
Ernexa Therapeutics Inc. filed an 8-K on October 15, 2026, disclosing that it made an investor presentation available…
8-K — Impact 2/10
Oct 1, 2026 Press
Ernexa Therapeutics announced the appointment of Dr. Robert J. Spiegel to its Board of Directors and provided a…
Impact 4/10
Sep 16, 2026 SEC
Ernexa Therapeutics Inc. filed an 8-K on September 16, 2026, disclosing a corporate fact sheet and an investor…
8-K — Impact 2/10
Sep 16, 2026 SEC
Ernexa Therapeutics appointed Robert J. Spiegel, M.D. to its board of directors, effective immediately. This is a…
8-K — Impact 2/10
Aug 31, 2026 Insider
Luther Sanjeev was granted 118,848 shares
President and CEO
Aug 31, 2026 Insider
Ratner Elena was granted 5,944 shares
Director

SecBot reports

6 filings · 7 press releases · 0 bullish · 1 bearish · 5 neutral
All ERNA filing & press-release reports (13)